Cited by 276Liver physiology and pathologyOrgan Transplantation Techniques and OutcomesTissue Engineering and Regenerative Medicine

Mitosis and Apoptosis in the Liver of Interleukin–6-Deficient Mice After Partial Hepatectomy

Open access
Sakamoto, Toshiki, Liu, Zejin, Murase, Noriko, Ezure, Tsukasa, Yokomuro, Shigeki, Poli, Valerie, Demetris, Anthony J.·1999·Hepatology

Abstract

Recently, it was shown that hepatocyte DNA synthesis after partial hepatectomy (PH) is impaired in interleukin–6-deficient (IL–6-/-) mice, which results in significantly delayed, but eventual, recovery of normal liver weight, compared with the IL–6+/+ controls. Four possible compensatory mechanisms might explain this phenomenon: 1) hepatocyte hypertrophy; 2) activation of the oval cell compartment and subsequent maturation to hepatocytes; 3) non–oval biliary epithelial cell (BEC) proliferation; and/or 4) differential rates of apoptotic cell death in the regenerating liver. These hypotheses were tested by subjecting IL–6-/- and IL–6+/+ mice to PH and determining sequential liver weight, histology, hepatocyte and BEC 5′–bromo–2′–deoxyuridine (BrdU) labeling, liver DNA content, α–fetoprotein (AFP) mRNA production, and apoptosis at several time points after PH. Consistent with previous studies, we show that the absence of IL–6 significantly impairs hepatocyte DNA synthesis and delays liver weight recovery after PH, but the defect observed in this study is less severe than that previously reported, and no excess mortality, massive necrosis on histology, nor differences in liver injury test are seen. Interestingly, the IL–6-/- mice show more hepatocyte BrdU pulse labeling than the IL–6+/+ controls at 24 hours, but less at 36, 48, and 60 hours. Continuous BrdU infusion up to 60 hours after PH showed a cumulative hepatocyte labeling index of 79.5% in IL–6+/+ mice and 70.8% in IL–6-/- mice, respectively (P < .03). However, despite a lower labeling index and significantly delayed weight recovery, hepatic mass was equally restored in the two groups by 96 hours. There was no evidence of oval cell proliferation in the IL–6-/- mice, as determined by routine histology and AFP mRNA analysis, and non–oval BEC proliferation was also slightly impaired in the IL–6-/- mice compared with the IL–6+/+ mice. In addition, liver DNA content per gram of liver showed an increase compared with normal at 60 hours in both groups, but by 96 hours, there was no difference between the two groups. Thus, neither oval cell nor BEC proliferation, nor hepatocyte hypertrophy, could account for the eventual equivalent weight recovery. There was, however, a difference between the two groups in the rate of apoptosis. In normal livers of both IL–6-/- and IL–6+/+ mice, apoptotic cells were uncommon, and even fewer such cells were detected at 24, 36, and 48 hours after PH. Between 60 and 96 hours after PH, a wave of apoptosis spread through the livers of both groups. The number of apoptotic cells was directly proportional to the magnitude of hepatocyte BrdU labeling and liver DNA content after PH, and the difference between the nadir of apoptosis at 24 hours and the peak at 96 hours was greater for the IL–6+/+ mice. In addition, a direct comparison between the two groups at 96 hours showed that hepatocyte apoptosis was significantly lower in the IL–6-/- versus the IL–6+/+ mice (P < .02). Treatment of the IL–6-/- mice with rIL–6 completely reversed the hepatocyte proliferation defect and increased the subsequent level of total apoptotic bodies. The fine control of liver weight recovery during regeneration after PH is a complex process that involves both mitosis and apoptosis. IL–6 affects this process by recruiting, and possibly synchronizing, the entry of hepatocytes into cell cycling, which quickly restores liver mass. However, this robust response generates superfluous hepatocytes, which are eliminated via apoptosis, similar to many other processes involving organ growth

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.510290244

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IL-6 is an important promoter of hepatocyte viability after PHx.

    “As IL-6 is an important promoter of hepatocyte viability after PHx [23]”

    From Synthesis of IL-6 by Hepatocytes Is a Normal Response to Common Hepatic Stimuli (2014) · cites this paper as [23]

    The Discussion (page not available in our copy) reports less hepatocyte apoptosis after partial hepatectomy in IL-6-deficient mice, not greater hepatocyte survival with IL-6. It finds that IL-6 increases hepatocyte DNA synthesis and speeds liver-weight recovery, but those findings do not establish the attributed claim about viability. (LLM, conf=0.84)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • Similar results (no significant difference in remnant liver growth) have been reported with a different strain of IL-6-deficient mice.

    “Simi-lar results have been reported with a different strain of IL-6 -deficient mice.16”

    From Interleukin 6 Is Important for Survival After Partial Hepatectomy in Mice (2003) · cites this paper as [16]

    The “Sequential Liver Weight Before and After PH” section reports that liver-weight recovery was significantly impaired in IL-6-deficient mice at 48, 60, and 72 hours. The groups reached the same percentage of normal liver weight by 96 hours, so the claim holds for that endpoint but not for remnant liver growth throughout recovery. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 40 · Cited by 276

Research works printed but not linked: 33

  1. Ross R. Rous Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. Am J Pathol 1993;143:987-1002.
  2. Fausto N, Laird AD, Webber EM. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995;9:1527- 1536.
  3. Rai RM, Yang SQ, McClain C, Karp CL, Klein AS, Diehl AM. Kupffer cell depletion by gadolinium chloride enhances liver regeneration after partial hepatectomy in rats. Am J Physiol 1996;270:G909-G918.
  4. Matsumoto K, Fujii H, Michalopoulos G, Fung JJ, Demetris AJ. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. HEPATOLOGY 1994;20:376-382.
  5. Okada K, Shimizu Y, Nambe S, Kiguchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994;9:462-467.
  6. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-1196.
  7. Higgins GM, Anderson RM. Experimental pathology of the liver. I. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol 1931;12:186-202.
  8. Weghorst CM, Henneman JR, Ward JM. Dose response of hepatic and renal DNA synthetic rates to continuous exposure of bromodeoxyuri- dine (BrdU) via slow-release pellets or osmotic minipumps in male B6C3F1 mice. J Histochem Cytochem 1991;39:177-84.
  9. Goldsworthy TL, Fransson-Steen R, Maronpot RR. Importance of and approaches to quantification of hepatocyte apoptosis. Toxicol Pathol 1996;24:24-35.
  10. Wan Y, Freeswick PD, Khemlani LS, Kispert PH, Wang SC, Su GL, Billiar TR. Role of lipopolysaccharide (LPS), interleukin-1, interleukin-6, tumor necrosis factor, and dexamethasone in regulation of LPS-binding protein expression in normal hepatocytes and hepatocytes from LPS-treated rats. Infect Immun 1995;63:2435-2442.
  11. Lombardo YB, Menahan LA. Gluconeogenesis in perfused livers of genetically obese-hyperglycemic (ob/ob) mice. Horm Metab Res 1979;11: 9-14.
  12. Hofstetter JR, Zhang A, Mayeda AR, Guscar T, Nurnberger JI Jr., Lahiri DK. Genomic DNA from mice: a comparison of recovery methods and tissue sources. Biochem Mol Med 1997;62:197-202.
  13. Skelly SM, Tackney C, Hicklin D, Tamkins T, Goldstein N, Waksal H, Dagan S. High-level expression of a biologically active human interleu- kin-6 mutein. J Biotechnol 1994;34:79-86.
  14. Cotran RS, Kumar V, Robbins SL. Cellular injury and cellular death. In: Cotran RS, Kumar V, Robbins SL, eds. Pathologic Basis of Disease. 5th ed. Philadelphia: Saunders, 1994:1-34.
  15. Shulte-Hermann R, Grasl-Kraupp B, Bursch W. Apoptosis and hepatocar- cinogenesis. In: Jirtle RL, ed. Liver Regeneration and Carcinogenesis. Molecular and Cellular Mechanisms. San Diego, CA: Academic Press, 1995:141-178.
  16. Kuma S, Inaba M, Ogata H, Inaba K, Okumura T, Saito K, Yamamoto M, et al. Effect of human recombinant interleukin-6 on the proliferation of mouse hepatocytes in the primary culture. Immunobiology 1990;180:235- 242.
  17. Huggett AC, Ford CP, Thorgeirsson SS. Effects of interleukin-6 on the growth of normal and transformed rat liver cells in culture. Growth Factors 1989;2:83-89.
  18. Booth C, Potten CS. Effects of IL-11 on the growth of intestinal epithelial cells in vitro. Cell Prolif 1995;28:581-594.
  19. Fontaine V, Mahieu M, Content J. Interferon-gamma and interleukin-6 inhibit proliferation in human melanoma cells by different signalling pathways. Melanoma Res 1998;8:24-30.
  20. Huttner A, Lei T, Fahlbusch R, Schrell W, Adams EF. Relationship between cAMP induced inhibition of human meningioma cell prolifera- tion and autocrine secretion of interleukin-6. Life Sci 1996;58:1323- 1329.
  21. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993;120:1281-1288.
  22. Fan G, Kren BT, Steer CJ. Regulation of apoptosis-associated genes in the regenerating liver. Semin Liver Dis 1998;18:123-140.
  23. Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell 1997;88:315-321.
  24. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365.
  25. Braun L, Mead JE, Panzica M, Mikumo R, Bell GI, Fausto N. Transform- ing growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc Natl Acad Sci USA 1988;85:1539-1543.
  26. Kren BT, Trembley JH, Krajewski S, Behrens TW, Reed JC, Steer CJ. Modulation of apoptosis-associated genes bcl-2, bcl-x, and bax during rat liver regeneration. Cell Growth Differ 1996;7:1633-1642.
  27. Tzung SP, Fausto N, Hockenbery DM. Expression of Bcl-2 family during liver regeneration and identification of Bcl-x as a delayed early response gene. Am J Pathol 1997;150:1985-1995.
  28. Ezure T, Sakamoto T, Liu Z, Yokomuro S, Murase N, Demetris AJ. Interleukin-6 and uncompensated cirrhosis [Abstract]. HEPATOLOGY 1998;28:525A.
  29. Camargo CA Jr., Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. HEPATOLOGY 1997;26:1513-1520.
  30. Nagy P, Kiss A, Schnur J, Thorgeirsson SS. Dexamethasone inhibits the proliferation of hepatocytes and oval cells but not bile duct cells in rat liver. HEPATOLOGY 1998;28:423-429.
  31. Hirano T. Interleukin-6. In: Thomson AW, ed. The Cytokine handbook. 2nd ed. San Diego: Academic Press, 1994:145-168.
  32. Malaguarnera M, Di Fazio I, Laurino A, Ferlito L, Romano M, Trovato BA. Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment. Int J Clin Pharmacol Ther 1997;35:385-388.
  33. Mills JJ, Jirtle RL. Mechanisms of liver tumor promotion. In: Jirtle RL, ed. Liver Regeneration and Carcinogenesis. Molecular and Cellular Mechanisms. San Diego, CA: Academic Press, 1995:199-226. HEPATOLOGY Vol. 29, No. 2, 1999

Authors
Sakamoto, T., Liu, Z., Murase, N., Ezure, T., Yokomuro, S., Poli, V., & Demetris, A. J.
Affiliations
University of Pittsburgh (US)
Corresponding author
Demetris, Anthony J.
Venue
Hepatology
Published
1999-02
Volume
29
Issue
2
Pages
403-411
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2078296217
Cited by
276
References
40
Citations by year
2026: 3 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 4 · 2019: 10 · 2018: 11 · 2017: 11 · 2016: 9 · 2015: 16 · 2014: 7 · 2013: 10 · 2012: 19
FWCI
7.51
Type
journal article
Language
en
Open access
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK049615, R01-DK49615-02)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
interleukin-6, partial hepatectomy, liver regeneration, hepatocyte DNA synthesis, apoptosis, hepatocyte proliferation, oval cells, cholangiocytes, alpha-fetoprotein, compensatory growth, hepatocyte hypertrophy, liver DNA content, BrdU labeling index, hepatocyte differentiation, liver injury
MeSH terms
alpha-Fetoproteins, Animals, Bile Ducts, Intrahepatic, Cell Division, DNA, Epithelial Cells, Female, Hepatectomy, Kinetics, Liver, Liver Regeneration, Mice, Mutant Strains, Mitosis, Organ Size, RNA, Messenger, Interleukin-6, Apoptosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review